RT Journal Article
SR Electronic
T1 Hyperglycemia in Acute COVID-19 is Characterized by Adipose Tissue Dysfunction and Insulin Resistance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.21.21254072
DO 10.1101/2021.03.21.21254072
A1 Reiterer, Moritz
A1 Rajan, Mangala
A1 Gómez-Banoy, Nicolás
A1 Lau, Jennifer D.
A1 Gomez-Escobar, Luis G.
A1 Gilani, Ankit
A1 Alvarez-Mulett, Sergio
A1 Sholle, Evan T.
A1 Chandar, Vasuretha
A1 Bram, Yaron
A1 Hoffman, Katherine
A1 Rubio-Navarro, Alfonso
A1 Uhl, Skyler
A1 Shukla, Alpana P.
A1 Goyal, Parag
A1 tenOever, Benjamin R.
A1 Alonso, Laura C.
A1 Schwartz, Robert E.
A1 Schenck, Edward J.
A1 Safford, Monika M.
A1 Lo, James C.
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.21.21254072.abstract
AB COVID-19 has proven to be a metabolic disease resulting in adverse outcomes in individuals with diabetes or obesity. Patients infected with SARS-CoV-2 and hyperglycemia suffer from longer hospital stays, higher risk of developing acute respiratory distress syndrome (ARDS), and increased mortality compared to those who do not develop hyperglycemia. Nevertheless, the pathophysiological mechanism(s) of hyperglycemia in COVID-19 remains poorly characterized. Here we show that insulin resistance rather than pancreatic beta cell failure is the prevalent cause of hyperglycemia in COVID-19 patients with ARDS, independent of glucocorticoid treatment. A screen of protein hormones that regulate glucose homeostasis reveals that the insulin sensitizing adipokine adiponectin is reduced in hyperglycemic COVID-19 patients. Hamsters infected with SARS-CoV-2 also have diminished expression of adiponectin. Together these data suggest that adipose tissue dysfunction may be a driver of insulin resistance and adverse outcomes in acute COVID-19.Competing Interest StatementR.E.S. is on the scientific advisory board of Miromatrix Inc. R.E.S. is a speaker and consultant for Alnylam Inc. The other authors have no conflict of interest.Funding StatementThis work was supported by the following grants: NIH R01 DK121140 (J.C.L.) and R01 DK121844 (J.C.L.), NCI R01 CA234614 (R.E.S), NIAID 2R01 AI107301 (R.E.S), and NIDDK R01 DK121072 (R.E.S). R.E.S. is supported as Irma Hirschl Trust Research Award Scholars. In addition, this study received support from NewYork-Presbyterian Hospital (NYPH) and Weill Cornell Medical College (WCMC), including the Clinical and Translational Science Center (CTSC) (UL1 TR 0002384). The views expressed in this manuscript are those of the authors and do not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The registry was approved by the institutional review board of WCMC (1405015116, 20-05022072, 20-03021681).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll requests for raw and analyzed data will be reviewed to verify if the request is subject to any intellectual property or confidentiality obligations. Any data and materials that can be shared will be released via a Material Transfer Agreement.